Advanced search
Add to list

Platelet/Leukocyte Activation, Inflammation, and Uremia

(2009) SEMINARS IN DIALYSIS. 22(4). p.423-427
Author
Organization
Abstract
Chronic kidney disease (CKD) is a state of chronic, low-grade inflammation which contributes to the accelerated progression of chronic inflammatory disturbances of which atherosclerosis is a major example. Platelet and leukocyte activation and interaction, evoked by the uremic condition, play an important role in this process. The effect of specific uremic retention solutes, progressively retained in uremia, on important platelet and leukocytes functions is discussed and summarized. The main uremic toxins involved are molecules with a molecular weight above 500 Da (the so-called "middle molecules") and/or protein-bound molecules. Classification of the molecules and elucidation of the pathophysiological pathways involved will result in new therapeutic strategies pursuing specific removal or pharmacological neutralization of molecular impact.
Keywords
PHENYLACETIC ACID, FACTOR-ALPHA, BLOOD MONONUCLEAR-CELLS, CHRONIC KIDNEY-DISEASE, TUBULAR EPITHELIAL-CELLS, CHRONIC-RENAL-FAILURE, DIADENOSINE POLYPHOSPHATES, POLYMORPHONUCLEAR LEUKOCYTES, HEMODIALYSIS-PATIENTS, PLATELET ACTIVATION

Citation

Please use this url to cite or link to this publication:

MLA
Glorieux, Griet et al. “Platelet/Leukocyte Activation, Inflammation, and Uremia.” SEMINARS IN DIALYSIS 22.4 (2009): 423–427. Print.
APA
Glorieux, G., Cohen, G., Jankowski, J., & Vanholder, R. (2009). Platelet/Leukocyte Activation, Inflammation, and Uremia. SEMINARS IN DIALYSIS, 22(4), 423–427.
Chicago author-date
Glorieux, Griet, G Cohen, J Jankowski, and Raymond Vanholder. 2009. “Platelet/Leukocyte Activation, Inflammation, and Uremia.” Seminars in Dialysis 22 (4): 423–427.
Chicago author-date (all authors)
Glorieux, Griet, G Cohen, J Jankowski, and Raymond Vanholder. 2009. “Platelet/Leukocyte Activation, Inflammation, and Uremia.” Seminars in Dialysis 22 (4): 423–427.
Vancouver
1.
Glorieux G, Cohen G, Jankowski J, Vanholder R. Platelet/Leukocyte Activation, Inflammation, and Uremia. SEMINARS IN DIALYSIS. MALDEN: WILEY-BLACKWELL PUBLISHING, INC; 2009;22(4):423–7.
IEEE
[1]
G. Glorieux, G. Cohen, J. Jankowski, and R. Vanholder, “Platelet/Leukocyte Activation, Inflammation, and Uremia,” SEMINARS IN DIALYSIS, vol. 22, no. 4, pp. 423–427, 2009.
@article{849534,
  abstract     = {Chronic kidney disease (CKD) is a state of chronic, low-grade inflammation which contributes to the accelerated progression of chronic inflammatory disturbances of which atherosclerosis is a major example. Platelet and leukocyte activation and interaction, evoked by the uremic condition, play an important role in this process. The effect of specific uremic retention solutes, progressively retained in uremia, on important platelet and leukocytes functions is discussed and summarized. The main uremic toxins involved are molecules with a molecular weight above 500 Da (the so-called "middle molecules") and/or protein-bound molecules. Classification of the molecules and elucidation of the pathophysiological pathways involved will result in new therapeutic strategies pursuing specific removal or pharmacological neutralization of molecular impact.},
  author       = {Glorieux, Griet and Cohen, G and Jankowski, J and Vanholder, Raymond},
  issn         = {0894-0959},
  journal      = {SEMINARS IN DIALYSIS},
  keywords     = {PHENYLACETIC ACID,FACTOR-ALPHA,BLOOD MONONUCLEAR-CELLS,CHRONIC KIDNEY-DISEASE,TUBULAR EPITHELIAL-CELLS,CHRONIC-RENAL-FAILURE,DIADENOSINE POLYPHOSPHATES,POLYMORPHONUCLEAR LEUKOCYTES,HEMODIALYSIS-PATIENTS,PLATELET ACTIVATION},
  language     = {eng},
  number       = {4},
  pages        = {423--427},
  publisher    = {WILEY-BLACKWELL PUBLISHING, INC},
  title        = {Platelet/Leukocyte Activation, Inflammation, and Uremia},
  url          = {http://dx.doi.org/10.1111/j.1525-139X.2009.00593.x},
  volume       = {22},
  year         = {2009},
}

Altmetric
View in Altmetric
Web of Science
Times cited: